Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Increased risk of recurrence and disease-specific death following delayed postoperative radiation for Merkel cell carcinoma.

Autor: Alexander NA; Department of Dermatology, University of Washington, Seattle, Washington; Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri., Schaub SK; Department of Radiation Oncology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. Electronic address: skschaub@uw.edu., Goff PH; Department of Radiation Oncology, University of Washington, Seattle, Washington., Hippe DS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Park SY; Department of Dermatology, University of Washington, Seattle, Washington., Lachance K; Department of Dermatology, University of Washington, Seattle, Washington., Bierma M; Department of Dermatology, University of Washington, Seattle, Washington., Liao JJ; Department of Radiation Oncology, University of Washington, Seattle, Washington., Apisarnthanarax S; Department of Radiation Oncology, University of Washington, Seattle, Washington., Bhatia S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington., Tseng YD; Department of Radiation Oncology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Nghiem PT; Department of Dermatology, University of Washington, Seattle, Washington., Parvathaneni U; Department of Radiation Oncology, University of Washington, Seattle, Washington.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Feb; Vol. 90 (2), pp. 261-268. Date of Electronic Publication: 2023 Sep 30.

Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma.

Autor: Tachiki LML; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. ltachiki@uw.edu.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ltachiki@uw.edu., Hippe DS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Silva KW; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hall ET; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., McCamy W; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA., Fritzsche D; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Perdue A; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Majovski J; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Pulliam T; Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Goldstein DA; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel., Veatch J; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Ho J; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Nghiem PT; Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Thompson JA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Bhatia S; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. sbhatia@uw.edu.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. sbhatia@uw.edu.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Dec; Vol. 72 (12), pp. 4471.

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.

Autor: D'Angelo SP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA. Electronic address: dangelos@mskcc.org., Bhatia S; Department of Medicine, University of Washington Medical Center, Seattle, USA., Brohl AS; Sarcoma Department and Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA., Hamid O; Department of Medical Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, USA., Mehnert JM; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA., Terheyden P; Department of Dermatology, University of Lübeck, Lübeck, Germany., Shih KC; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, USA; Department of Medical Oncology, Tennessee Oncology, Nashville, USA., Brownell I; Dermatology Branch, National Institutes of Health, Bethesda, USA., Lebbé C; Université de Paris, INSERM U976, Paris, France; Dermatology and CIC, AP-HP, Saint Louis Hospital, Paris, France., Lewis KD; Department of Medicine, University of Colorado Denver School of Medicine, Aurora, USA., Linette GP; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA., Milella M; Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust (AOUI Verona), Verona, Italy., Xiong H; Biostatistics, EMD Serono Research & Development Institute, Inc., Billerica, USA, an affiliate of Merck KGaA., Guezel G; Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Nghiem PT; Division of Dermatology, Department of Medicine, University of Washington Medical Center at South Lake Union, Seattle, USA.

Publikováno v: ESMO open [ESMO Open] 2021 Dec; Vol. 6 (6), pp. 100290. Date of Electronic Publication: 2021 Oct 26.

Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.

Autor: Lahman MC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA., Paulson KG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA; Medical Oncology, Swedish Cancer Institute, Seattle, Washington, USA; Elson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA., Nghiem PT; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA., Chapuis AG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA. Electronic address: achapuis@fredhutch.org.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2021 Aug; Vol. 141 (8), pp. 1897-1905. Date of Electronic Publication: 2021 Apr 13.